JP2020063241A5 - - Google Patents

Download PDF

Info

Publication number
JP2020063241A5
JP2020063241A5 JP2019185670A JP2019185670A JP2020063241A5 JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5 JP 2019185670 A JP2019185670 A JP 2019185670A JP 2019185670 A JP2019185670 A JP 2019185670A JP 2020063241 A5 JP2020063241 A5 JP 2020063241A5
Authority
JP
Japan
Prior art keywords
conjugate
linker
tate
targeting moiety
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019185670A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932389B2 (ja
JP2020063241A (ja
Filing date
Publication date
Priority claimed from JP2017500064A external-priority patent/JP6602834B2/ja
Application filed filed Critical
Publication of JP2020063241A publication Critical patent/JP2020063241A/ja
Publication of JP2020063241A5 publication Critical patent/JP2020063241A5/ja
Priority to JP2021131359A priority Critical patent/JP2021175757A/ja
Application granted granted Critical
Publication of JP6932389B2 publication Critical patent/JP6932389B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019185670A 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤 Expired - Fee Related JP6932389B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131359A JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462019001P 2014-06-30 2014-06-30
US62/019,001 2014-06-30
US201462077487P 2014-11-10 2014-11-10
US62/077,487 2014-11-10
US201562150413P 2015-04-21 2015-04-21
US62/150,413 2015-04-21
JP2017500064A JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017500064A Division JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131359A Division JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Publications (3)

Publication Number Publication Date
JP2020063241A JP2020063241A (ja) 2020-04-23
JP2020063241A5 true JP2020063241A5 (enExample) 2020-06-11
JP6932389B2 JP6932389B2 (ja) 2021-09-08

Family

ID=55020088

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤
JP2019185670A Expired - Fee Related JP6932389B2 (ja) 2014-06-30 2019-10-09 標的化コンジュゲートならびにその粒子及び製剤
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017500064A Expired - Fee Related JP6602834B2 (ja) 2014-06-30 2015-06-30 標的化コンジュゲートならびにその粒子及び製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131359A Pending JP2021175757A (ja) 2014-06-30 2021-08-11 標的化コンジュゲートならびにその粒子及び製剤

Country Status (15)

Country Link
US (4) US9750818B2 (enExample)
EP (1) EP3160518A4 (enExample)
JP (3) JP6602834B2 (enExample)
KR (2) KR20190143491A (enExample)
CN (2) CN106573077B (enExample)
AU (2) AU2015284236B2 (enExample)
BR (1) BR212016030926U2 (enExample)
CA (1) CA2953371C (enExample)
IL (1) IL249647B (enExample)
MX (1) MX379365B (enExample)
PH (1) PH12017500023A1 (enExample)
RU (1) RU2695220C2 (enExample)
SG (1) SG11201610880RA (enExample)
WO (1) WO2016004048A2 (enExample)
ZA (1) ZA201608432B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190015350A1 (en) 2013-02-05 2019-01-17 Anp Technologies, Inc. Nanoparticles Containing a Taxane and their Use
US9533054B2 (en) * 2013-03-11 2017-01-03 Shanghai Jiao Tong University Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
CN106573077B (zh) 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
KR20180021742A (ko) * 2015-06-30 2018-03-05 타베다 세라퓨틱스, 인코포레이티드 표적화된 접합체 및 이의 입자 및 제형
SG10201912394VA (en) * 2015-07-15 2020-02-27 Celator Pharmaceuticals Inc Improved nanoparticle delivery systems
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10039801B2 (en) 2016-02-16 2018-08-07 Strongbridge Ireland Limited Pharmaceutical compositions of water soluble peptides with poor solubility in isotonic conditions and methods for their use
WO2017161096A1 (en) * 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles
WO2017180834A1 (en) * 2016-04-13 2017-10-19 Tarveda Therapeutics, Inc. Neurotensin receptor binding conjugates and formulations thereof
WO2017210246A2 (en) * 2016-05-31 2017-12-07 Tarveda Therapeutics, Inc. Penicillamine conjugates and particles and formulations thereof
EP3507295A1 (en) * 2016-08-31 2019-07-10 Mireca Medicines GmbH New polymer linked multimers of guanosine-3', 5'-cyclic monophosphates
WO2018081521A1 (en) * 2016-10-28 2018-05-03 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
JP7493796B2 (ja) * 2017-07-11 2024-06-03 サステインドナノシステムズエルエルシー 超圧縮医薬製剤
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
US20200230068A1 (en) * 2017-08-25 2020-07-23 Nal Pharmaceutical Group Limited Compositions and methods of delivery of pharmacological agents
US20200281934A1 (en) * 2017-10-27 2020-09-10 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and formulations thereof
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
WO2019232366A1 (en) * 2018-06-01 2019-12-05 Tarveda Therapeutics, Inc. Combination therapy
CN109124096B (zh) * 2018-08-23 2021-08-06 广州百隆威尔精密五金制品有限公司 一种升降橱柜
US12195552B2 (en) * 2018-12-17 2025-01-14 Remegen Co., Ltd. Linker for antibody-drug conjugates and its use
EP3941508A1 (en) * 2019-03-18 2022-01-26 The Trustees of Columbia University in the City of New York Non-hydrolyzable, non-cleavable, stable linkers for precision therapeutics and uses thereof
CN109848440A (zh) * 2019-04-10 2019-06-07 燕山大学 一种钯纳米立方体的制备方法
AU2020307561A1 (en) * 2019-06-25 2022-01-20 Tva (Abc), Llc SSTR-targeted conjugates and formulations thereof
EP4106828B1 (en) 2020-02-21 2026-03-11 Tonic Medical, Inc. Polymer-encapsulated drug particles
CN112250647A (zh) * 2020-06-30 2021-01-22 浙江大学 紫杉烷类药物前体、制备方法和应用
IL303813A (en) 2020-12-21 2023-08-01 Univ Cornell Peptide-linked drug delivery system
WO2022174171A1 (en) 2021-02-15 2022-08-18 Anp Technologies, Inc. Pharmaceutical composition containing taxane nanoaggregates and use thereof
US20220296514A1 (en) * 2021-03-18 2022-09-22 FormuRx Pharmaceuticals Co., Ltd. Composition and Method of Preparation for Lipid Formulations Comprising Charged Lipids
EP4312941A4 (en) * 2021-04-01 2025-02-26 R.P. Scherer Technologies, LLC Phospholipids as anion chelating agents in pharmaceutical formulations
IT202100014330A1 (it) * 2021-06-01 2022-12-01 The Ubeauty Com Llc Prodotto per la cura della pelle e procedimento per la sua realizzazione.
CN118005545B (zh) * 2024-01-04 2025-02-18 兰州大学 小分子抗菌肽模拟物及其应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
AT405906B (de) 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) * 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
AU1360901A (en) * 1999-11-01 2001-05-14 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
DE10006572A1 (de) * 2000-02-14 2001-08-23 Deutsches Krebsforsch Oligonucleotid-Konjugate
FR2824563B1 (fr) * 2001-05-10 2004-12-03 Bio Merieux Particules composites, conjugues derives, procede de preparation et applications
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1531846A4 (en) 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
MXPA04008419A (es) 2002-03-01 2004-11-26 Univ Tulane Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
KR101476067B1 (ko) * 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
WO2004080483A1 (en) 2003-03-10 2004-09-23 Mpa Technologies, Inc. Targeted agents for both photodiagnosis and photodynamic therapy
EP1624884A4 (en) * 2003-04-22 2009-08-05 Ipsen Pharma SOMATOSTATIN VECTORS
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CR20170291A (es) * 2003-05-20 2017-07-27 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
JP4318985B2 (ja) * 2003-08-21 2009-08-26 日本メジフィジックス株式会社 ソマトスタチンアナログ誘導体およびその利用
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
EP1864682A1 (en) 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
US20110059142A1 (en) * 2008-05-06 2011-03-10 Irene Papanicolaou Encapsulation of biologically active agents
EA019507B1 (ru) 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
AU2009292643B2 (en) * 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
EP2449379B1 (en) * 2009-07-02 2017-05-17 Sloan-Kettering Institute for Cancer Research Fluorescent silica-based nanoparticles
JP5892540B2 (ja) 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
JP5827218B2 (ja) * 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
TW201302793A (zh) * 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
BR112013005711A2 (pt) * 2010-09-08 2017-06-13 Univ Texas método para tratar um tumor, mutante, molécula de ácido nucleico isolada, construção de expressão, composição, e, método para administrar uma terapia
CN103687627A (zh) * 2011-03-01 2014-03-26 通用电气健康护理有限公司 作为pet示踪剂的放射性标记的奥曲肽酸类似物
WO2012138911A2 (en) * 2011-04-05 2012-10-11 The Administrators Of The Tulane Educational Fund Conjugates of anti-hiv drugs and somatostatin analogs
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
JP6215194B2 (ja) * 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
SG10201605041VA (en) 2011-06-21 2016-08-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
CN104302408B (zh) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
KR20150056619A (ko) * 2012-09-17 2015-05-26 바인드 쎄라퓨틱스, 인크. 치료제를 포함하는 치료 나노입자 및 그의 제조 및 사용 방법
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3057991B8 (en) 2013-10-15 2019-09-04 The Scripps Research Institute Chimeric antigen receptor t cell switches and uses thereof
CN106573077B (zh) * 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂

Similar Documents

Publication Publication Date Title
JP2020063241A5 (enExample)
JP6092867B2 (ja) 担体連結しているトレプロスチニルプロドラッグ
US9096642B2 (en) Therapeutic compounds for immunomodulation
US20060051315A1 (en) Polymers for delivering peptides and small molecules in vivo
RU2548905C2 (ru) Терапевтические пептиды
JP2020514300A5 (enExample)
CN103874480A (zh) 前列环素的缓释组合物
JPWO1999061061A1 (ja) 薬物複合体
JP2010521485A5 (enExample)
RU2007131504A (ru) Пептиды, обладающие агонистической активностью в отношении рецептора нейропептида-2-(y2r)
JP2012067100A (ja) Ｉｌ−２１の誘導体
EP2485712A1 (en) Subcutaneous paliperidone composition
US11077082B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
TW202500573A (zh) 細胞穿透肽序列
US20170014524A1 (en) Auristatin-antibody conjugates and uses thereof
US8518891B2 (en) Chemotherapeutic conjugates and methods of use
KR101828613B1 (ko) 올리고머-칼슘 모방체 컨쥬게이트 및 관련 화합물
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
EP3946635A2 (en) Locally acting toll-like receptor 7 (tlr7) and/or tlr8 agonist immunotherapy compounds and their uses
EP1372733B1 (en) Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration
US20220362278A1 (en) Renal targeting-type drug delivery carrier having excellent biodegrability
US11351137B2 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors
KR20170091610A (ko) 신규 peg 유도체
RU2789198C2 (ru) Композиция и способ двойного нацеливания при лечении нейроэндокринных опухолей
CA3220332A1 (en) Composition and method for dual targeting in treatment of neuroendocrine tumors